These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23418418)

  • 1. Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI.
    Park KW; Park JJ; Kang J; Jeon KH; Kang SH; Han JK; Lee SE; Yang HM; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS
    PLoS One; 2013; 8(2):e52779. PubMed ID: 23418418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy.
    Tselepis AD; Tsoumani ME; Kalantzi KI; Dimitriou AA; Tellis CC; Goudevenos IA
    J Thromb Haemost; 2011 Dec; 9(12):2371-8. PubMed ID: 22008470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.
    Mega JL; Close SL; Wiviott SD; Man M; Duvvuru S; Walker JR; Sundseth SS; Collet JP; Delaney JT; Hulot JS; Murphy SA; Paré G; Price MJ; Sibbing D; Simon T; Trenk D; Antman EM; Sabatine MS
    J Thromb Thrombolysis; 2016 Apr; 41(3):374-83. PubMed ID: 26573179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention.
    Olędzki S; Kornacewicz-Jach Z; Safranow K; Kiedrowicz R; Gawrońska-Szklarz B; Jastrzębska M; Gorący J
    Eur J Clin Pharmacol; 2017 Sep; 73(9):1085-1094. PubMed ID: 28589365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
    Nishio R; Shinke T; Otake H; Nakagawa M; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Kuroda M; Hirata K
    Thromb Res; 2013 Nov; 132(5):558-64. PubMed ID: 24080149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
    Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T
    Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting.
    Ma W; Liang Y; Zhu J; Chen T; Feng G; Yang Y; Liu X; Wang X
    Atherosclerosis; 2016 Aug; 251():305-310. PubMed ID: 27450784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
    Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement.
    Trenk D; Hochholzer W; Fromm MF; Zolk O; Valina CM; Stratz C; Neumann FJ
    Circ Cardiovasc Genet; 2011 Aug; 4(4):429-36. PubMed ID: 21685174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention.
    Zhang Z; Chen M; Zhang L; Zhao Q
    BMC Pharmacol Toxicol; 2020 Jan; 21(1):1. PubMed ID: 31900240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
    Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
    Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents.
    Park JJ; Park KW; Kang J; Jeon KH; Kang SH; Ahn HS; Han JK; Koh JS; Lee SE; Yang HM; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS
    Int J Cardiol; 2013 Feb; 163(1):79-86. PubMed ID: 23260377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G
    Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrinsic platelet reactivity before start with clopidogrel as predictor for on-clopidogrel platelet function and long-term clinical outcome.
    Hochholzer W; Valina CM; Bömicke T; Amann M; Stratz C; Nührenberg T; Trenk D; Neumann FJ
    Thromb Haemost; 2015 Jul; 114(1):109-14. PubMed ID: 25832119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients.
    Yang J; Zhou JS; Tan J; He BS; Zou JJ
    Pharmazie; 2012 Dec; 67(12):1026-9. PubMed ID: 23346768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.